Biotech News

Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update

Arvinas, Inc. (ARVN)ir.arvinas.com2026-05-12 11:08 ESTFDA / regulatory

– First-ever FDA approved PROTAC supports the further development and potential of Arvinas’ pipeline – – Announced FDA Approval of VEPPANU ™ (vepdegestrant) for the treatment of ESR1m, ER+/HER2- advanced breast cancer – – Announced selection of Rigel Pharmaceuticals for the exclusive global rights

Open original release

Related news

No closely related headlines were available from the latest feed snapshot.

View all latest news

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-05-29 16:07:30 EST

Arvinas to Present at Jefferies Global Healthcare Conference

ARVNArvinas, Inc.2026-05-18 10:37:52 EST

Arvinas Employees Give Back During Company-wide Impact Day

ARVNArvinas, Inc.2026-05-12 07:08:35 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

ARVNArvinas, Inc.2026-05-06 10:53:23 EST

Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States